Resumen
Lung cancer stands as the leading cause of cancer-related fatalities both in China and worldwide, underscoring the critical need for effective therapeutic approaches. At present, the primary treatment modalities for non-small cell lung cancer (NSCLC) include chemotherapy, targeted therapy, and immunotherapy. Within this investigation, we demonstrate that the synergistic effects of anti-CD47 and CTLA4 blockade in immunotherapy yield an efficient anti-tumor impact on NSCLC. Furthermore, our study elucidates the underlying mechanisms of this combined therapeutic approach. In conclusion, our research provides compelling evidence supporting the efficacy of the anti-CD47 antibody and anti-CTLA4 antibody combination in treating NSCLC, thereby proposing meaningful avenues for future clinical trials addressing NSCLC.